FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to medical biotechnology. Disclosed are antibodies and their antigen-binding fragments, which can bind to the antigen SARS-CoV-2 (coronavirus-2 of severe acute respiratory syndrome) and in some embodiments are able to neutralize infection with SARS-CoV-2. Also disclosed are polynucleotides encoding an antibody or antigen-binding fragment, a recombinant expression vector for producing an antibody, host cells containing a polynucleotide, pharmaceutical compositions for treating SARS-CoV-2 infection, an aerosol composition delivery kit and methods of using the disclosed antibodies, antigen-binding fragments and compositions in preparing a medicament for treating a SARS-CoV-2 infection in a subject or diagnosing a SARS-CoV-2 infection. Invention also discloses an in vitro method of producing an antibody and a method of treating a SARS-CoV-2 infection in a subject.
EFFECT: invention enables preventing or treating SARS-CoV-2 infections or diagnosing SARS-CoV-2 infections.
62 cl, 148 dwg, 13 tbl, 39 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
| PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
| METHOD OF INCREASING IMMUNOGENICITY OF PROTEIN/PEPTIDE ANTIGEN | 2021 |
|
RU2830627C1 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| MESSENGER RNA VACCINES AGAINST WIDE RANGE OF CORONAVIRUS VARIANTS | 2022 |
|
RU2826172C2 |
| GENE CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT PROTEINS BASED ON THE SEGMENT OF THE SARS-COV-2 S-PROTEIN, INCLUDING RBD AND SD1, FUSED WITH THE FC FRAGMENT OF IGG, A METHOD OF OBTAINING RECOMBINANT PROTEINS, ANTIGENS AND ANTIGENIC COMPOSITIONS FOR THE INDUCTION OF LONG-TERM ANTIBODY AND CELLULAR IMMUNITY AGAINST SARS-CO-2 | 2021 |
|
RU2802825C2 |
